中华检验医学杂志最新文献

{"title":"Expression level and clinical significance of serum exosomal miR-744-5p in non-small cell lung cancer","authors":"Shao-Ping Li, Xin Zhang, Han-Chao Zhang","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.008","url":null,"abstract":"Objective \u0000To analysis the expression level and clinical value of serum exosomal miR-744-5p in non-small cell lung cancer (NSCLC). \u0000 \u0000 \u0000Methods \u0000Retrospective study. A total of 183 subjects, including 92 NSCLC patients and 91 healthy controls, were recruited from Nanfang Hospital Affiliated to Southern Medical University from November 2016 to February 2018. Exosomes were extracted using ExoQuick and the total RNA was extracted from the exosomes.The expression level of serum exosomal miR-744-5p was assessed by real-time fluorescent quantitative polymerase chain reaction (qRT-PCR). The diagnostic efficiency of exosomal miR-744-5p was evaluated by receiver operating characteristic (ROC) curve. \u0000 \u0000 \u0000Results \u0000The qRT-PCR results revealed that the expression level of serum exosomal miR-744-5p in patients with NSCLC (0.012 2±0.019 7) was significantly lower than that in the healthy control (0.093 6±0.081 9), and the difference was statistically significant (U=553.5, P<0.001). Furthermore, the level of miR-744-5p in patients with early stage (stage Ⅰ and Ⅱ) lung cancer(0.011 7±0.013 9) was significantly different, when compared to healthy controls (U=72.5, P<0.001). The exosomal level of miR-744-5p in samples (0.010 6±0.020 3) was lower than that in squamous cell carcinoma serum (0.017 3±0.017 8) , and the difference was statistically significant (U=394.5, P<0.001). The ROC curve revealed that miR-744-5p expression can be a significant biomarker to discriminate between normal and NSCLC cases, with an area under the ROC curve of 0.933 9 (95%CI=0.899 6-0.968 1, P<0.000 1). MiR-744-5p can effectively diagnose early stage NSCLC, with an area under the ROC curve of 0.943 1 (95%CI=0.883 7-1.000 0, P<0.000 1). \u0000 \u0000 \u0000Conclusion \u0000The serum exosomal miR-744-5p could serve as a non-invasive biomarker for the diagnosis of NSCLC, but further comparative research and expanded verification are needed. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Exosomes; microRNAs; Biomarkers, tumor","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"23 1","pages":"142-146"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81759856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Cell Receptors for Human Coronavirus","authors":"Li Yan, J. Xiang, T. Cui","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.03.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.03.006","url":null,"abstract":"Liquid biopsy can non-invasively reveal the status of tumors in vivo, and provides a powerful basis for early diagnosis, personalized treatment monitoring and prognosis prediction. According to the type of tumor-associated material, liquid biopsy covers circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs) and circulating tumor RNA (ctRNA) etc. At present, several liquid biopsy products havebeen approved for clinical use, while many transformation studies have been vigorously carried out. However, there are still many clinical challenges to be solved effectively. Despite the standardization of detection and quality management system of liquid biopsy are lagged with the rapid development of technology, liquid biopsy, as a highly promising detection technology, will become a reliable diagnostic tool with the increasing clinical requirements for facilitating the tumor management. \u0000 \u0000 \u0000Key words: \u0000Liquid biopsy; Tumor diagnosis and treatment; Clinical application","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"54 1","pages":"124-129"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80182022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research status and progress of Glypican-3 and liver carcinoma","authors":"M. Dong, Qi Li, Xiang-xiang Liu","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.018","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.018","url":null,"abstract":"Phosphatidylinositol protein 3 (Glypican-3, GPC3) is a cell-surface heparan sulfate proteoglycan that belongs to the glycine related global membrane proteoglycan relatives.Many studies have shown that it is of great significance in the occurrence, diagnosis, treatment and prognosis of hepatocellular carcinoma (HCC).This paper reviews the recent studies on GPC3. \u0000 \u0000 \u0000Key words: \u0000Liver neoplasms; Glypicans; Biomarkers, tumor; Prognosis","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"167 1","pages":"199-202"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73400567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interfering effect of maternal cell contamination on invasive prenatal chromosome microarray analysis","authors":"Sha Lu, Hao Wang, Dan Liang, Jie Ren, Wenshen Hu","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.010","url":null,"abstract":"Objective \u0000To access the effect of maternal cell contamination (MCC) on the detection of copy number variation (CNV) by chromosome microarray analysis (CMA) in prenatal diagnostic samples. \u0000 \u0000 \u0000Methods \u0000Amniotic fluid DNA samples were collected from Department of Prenatal Diagnosis (Screening) Centre of Hangzhou Women′s Hospital from December 2016 to August 2018. Copy number variations (CNVs) were identified in these DNA samples by CMA and normal female genomic DNA was added to simulate different proportions of maternal cells contamination. The simulated samples were tested using an Agilent microarray chromosome chip 180K CGH (Agilent 180K CGH) and the results were analyzed by Agilent CytoGenomics software. \u0000 \u0000 \u0000Results \u0000The results showed that duplications of CNV could not be detected at>38.4% MCC. Deletions of CNV could not be detected at>41.3% of MCC. With the increase of MCC ratio, the detection rate of CNV decreased gradually. The array and software allowed detection of longer copy-number variations at higher levels of maternal cell contamination than shorter copy-number variations. For the same size CNV, the detection ability of the deleted CNV was slightly higher than that of duplication. In the male sample, the observable shift of the X/Y chromosome ratio at>10% MCC can be detected by the microarray. \u0000 \u0000 \u0000Conclusions \u0000When the MCC is higher than a particular ratio, it can affect the CMA detection of CNV. Based on the Agilent 180K CGH detection results for MCC mimics and the CNV detection specificity principle, the MCC threshold of the Agilent 180K CGH is set to 30% in view of conservative principles. \u0000 \u0000 \u0000Key words: \u0000Amniotic fluid; Prenatal diagnosis; Microarray analysis; DNA copy number variations","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"7 1","pages":"153-159"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76992356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The alterations and clinical significance of serum S100A8/A9 and sRAGE in patients with chronic obstructive pulmonary disease","authors":"Z. Quan, Jing Chen, Xiaojie Wu, Xu Liu, Aili Wang, Shenggao Xie, Yueqin Wang, Rui Jiang, Shuang Zhang, Jungang Xie, T. Cui","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.012","url":null,"abstract":"Objective \u0000To analyze the alterations and clinical significance of serum calcium binding protein S100A8/A9 and soluble receptor for advanced glycation end products (sRAGE) levels in patients with chronic obstructive pulmonary disease(COPD). \u0000 \u0000 \u0000Methods \u0000Enzyme-linked immonosorbent assay was established to detect serum levels of S100A8/A9 and sRAGE in 203 patients with COPD[male166, female 37, aged 52-92 years, average years(69.72±9.079)] and in 41 smoking elderly non-COPD patients[male 35,female 6, aged 55-89 years, average years(68.66±8.74)], and 167 non-smoking healthy subjects as the control group[male 132, female 35, aged 57-92 years, average years(69.13±7.21)] from April 2018 to January 2019. The relationship between the S100A8/A9, sRAGE and clinical biomarkers [the percentage of fored expiratory volume in one second(FEV1) in the predicted value, FEV1/fored vital capacity(FVC), neutrophile granulocyte(NEU)%, pack-year] were investigated. The diagnostic value of S100A8/A9, sRAGE and their combined detection for COPD was analyzed using the subject operating characteristic curve. \u0000 \u0000 \u0000Results \u0000The serum S100A8/A9 level [(2.70±1.11)μg/ml] in COPD patients was significantly higher than that in the smoking control group [(1.65±0.63) μg/ml] and the non-smoking control group[(0.99±0.48)μg/ml], t=5.807, P<0.000 1; t=18.45, P<0.000 1. The serum S100A8/A9 levels in patients with COPD[GOLD Ⅰ(2.08±1.08) μg/ml, GOLDⅡ (2.58±1.06) μg/ml, GOLD Ⅲ (2.69±1.12) μg/ml, GOLDⅣ (2.95±1.10)μg/ml] were significantly higher than the non-smoking control group(0.99±0.48)μg/ml, t=6.616, P<0.000 1; t=14.56, P<0.000 1; t=17.10, P<0.000 1; t=18.09, P<0.000 1.The serum sRAGE level [(0.29±0.25)ng/ml] in COPD patients was significantly higher than that in the smoking control group[(0.60±0.24)ng/ml] and the non-smoking control group[(0.85±0.35)ng/ml], t=7.367, P<0.000 1; t=18.14, P<0.000 1. The serum sRAGE levels in patients with COPD[GOLD Ⅰ(0.46±0.40),GOLDⅡ (0.28±0.25),GOLD Ⅲ (0.29±0.25),GOLD Ⅳ (0.25±0.19)ng/ml] were significantly lower compared with non-smoking control group[(0.85±0.35)ng/ml], t=3.459, P=0.000 5; t=10.23, P<0.000 1; t=13.95, P<0.000 1; t=11.70, P<0.000 1. Serum S100A8/A9 levels were positively correlated with smoking amount and NEU% (r=0.458 5, P<0.000 1; r=0.228 3, P=0.001 1), negatively correlated with FEV1/FVC, the percentage of FEV1 in the predicted value, and sRAGE(r=-0.190 6, P=0.006 4; r=-0.186 3, P=0.007 8; r=-0.201 7, P=0.003 9). sRAGE levels were negatively correlated with NEU% (r=-0.155 9, P=0.026 4). In the ROC curve, the area under the curve of S100A8/A9, sRAGE and combined detection were 0.922[95%CI(0.897-0.947)], 0.926[95%CI(0.899-0.952)]and 0.966 [95%CI(0.950-0.983)], respectively. \u0000 \u0000 \u0000Conclusion \u0000S100A8/A9 and sRAGE are closely correlated with the degree of airflow constrains and the levels of serum inflammatory mediators, which are expected to be as potential biomarkers of COPD. \u0000 \u0000 \u0000Key words: \u0000Pulmonary disease, chronic obstructive; Calgr","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"33 1","pages":"165-170"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76627124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How far is the clinical application of EVs-based tumor diagnosis?","authors":"Yanjun Diao, Liu Yang","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.004","url":null,"abstract":"As a new type of paracrine/autocrine and remote signaling, extracellular vesicles (EVs) involved in almost the whole process of tumorigenesis, progression, metastasis, and drug resistance, which has greatly inspired tumor diagnosis and treatment. EVs have the great potential to be the blood or urine biomarkers and can be used for cancer diagnosis, prognosis and monitoring. Due to its great clinical application value, EVs have become a hotspot in cancer research in recent years. Therefore, in this review, the advantages, progression, and technical challenges of EVs biomarkers in clinical tumors diagnosis are discussed. \u0000 \u0000 \u0000Key words: \u0000Extracellular vesicles; Biomarkers, tumor; Early detection of cancer","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"99 1","pages":"115-119"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90504027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of four screening methods for group B streptococcus","authors":"Kankan Gao, Xiaoshan Guan, Q. Deng, Lei Deng, Sufei Zhu, Xiaodong Hua, F. Gao","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.015","url":null,"abstract":"Objective \u0000To evaluate diagnostic performance of Todd-Hewitt (T-H) broth culture method, direct culture method, liquid chromogenic culture method, and loop-mediated isothermal amplification (LAMP) method for screening group B streptococcus (GBS) during late pregnancy. \u0000 \u0000 \u0000Methods \u0000In the retrospective study, the rectal vaginal secretions samples were collected from pregnant women at 35 to 37 weeks at the obstetrics clinic of Guangzhou Women and Children′s Medical Center affiliated to Guangzhou Medical University during October 2016 to April 2018. For the purposes of clinical evaluation, T-H broth culture was used as the standard reference method, and double-blind trials were used to evaluate diagnostic performance of direct culture method, liquid chromogenic culture method, and LAMP method for screening group B streptococcus during late pregnancy in three research stages. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), coincidence rate and Yoden index for each method were calculated. Also, the level of agreement between each method and T-H broth was assessed using the kappa (k) coefficient. \u0000 \u0000 \u0000Results \u0000A total of 969 specimens were detected by the T-H enrichment culture method, and 90 were positive (9.3%). The sensitivities from high to low were LAMP method [100% (25/25)], direct culture method [81.5% (22/27), 95%CI:65.8%-97.1%], and liquid color culture method [71.1% (27/38), 95%CI:55.9%-86.2%]. Specificities were direct culture method [100% (282/282)], liquid color culture method [98.1% (455/464), 95%CI:96.8%-99.3%], and LAMP method [94.0% (125/133), 95%CI: 89.9%-98.1%]. The coincidence rates were direct culture method [98.4% (22+282)/309], liquid color culture method [96.0% (27+455)/502], and LAMP method [94.9% (25+125)/158]. The Kappa values of the direct culture method (0.889), LAMP method (0.832) and the enrichment culture method were all ≥0.75, and that of the liquid color culture method was 0.708. The false negative rate of direct culture method was 18.5% (5/27), and no false negative case by LAMP method, but its false positive rate was 6.0% (8/133). The false negative rate and false positive rate of liquid color culture method were 28.9% (11/38) and 1.9% (9/464), respectively. \u0000 \u0000 \u0000Conclusions \u0000Of the three screening methods compared in this study, only the LAMP method has the advantages in sensitivity, specificity, and coincidence rate compared with T-H enriched culture method, while the others have a certain degree of false negatives rate. The clinical laboratory can introduce these methods based on laboratory facilities and staffing, or refer to the European and American guidelines and combine the recommended antenatal GBS screening method with intrapartum nucleic acid amplification tests to best meet the clinical demands. \u0000 \u0000 \u0000Key words: \u0000Pregnancy trimester, third; Streptococcus agalactiae; Bacteriological techniques; Culture media; Nucleic acid amplification techniques; Sensitivity and","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"28 1","pages":"182-185"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85394162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoter methylation of SREBP-2 in circulating leukocytes correlates with relevant risk factors in patients with coronary artery disease","authors":"Chunyan Peng, Xiandong Li, Xunnan Zhang, Zheng Cao","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.017","url":null,"abstract":"Objective To examine the correlation between the promoter methylation of Sterol regulatory-element binding protein-2 (SREBP-2) and miR-33a expression as well as serum markers in patients with coronary artery disease (CAD). Methods The case-control study. 100 participants who underwent coronary angiography from August 2017 to April 2018 in TaiheHospital, Hubei University of Medicine, were recruited in this study.The methylation level of two fragments, including 12 CpG sites in the promoter region of SREBP-2, have been detected by pyrosequencing in 50 patients with coronary artery disease (CAD) and 50 non-CAD controls. Serum miR-33a level and a panel of 15 CAD related biomarkers were examined by qPCR and routine biochemistry methods. Results Methylation level of one CpG site (F1-4 loci) in SREBP-2 promoter region were significant higher in CAD patients than in controls(4.56%±0.70% vs 3.54%±0.72%, t=-3.864, P<0.001); methylation level of F1-4 site was negatively correlates with the serum miR-33a levels and high-density lipoprotein cholesterol (HDL-C) levels(r=-0.318, P=0.001; r=-0.225, P=0.024, respectively). Furthermore, F1-4 hypermethylation was an independent risk factor of CAD, independent of age, gender, histories of hypertension, hyperlipidemia, and diabetes(OR=2.452, 95%CI=1.398-4.299, P=0.002). Conclusion These results suggest that DNA methylation and miRNA might cooperate to regulate the lipid metabolism in CAD. Key words: Coronary disease; Sterol regulatory element binding protein 2; DNA methylation; microRNAs; Lipid metabolism disorders","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"50 1","pages":"191-198"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91300345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA analysis:from discovery to clinical practice","authors":"Rui Zhang","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.001","url":null,"abstract":"Circulating tumor DNA analysis is the focused issue in clinical research. A few of biomarkers have been used in clinical practice, while some are in the discovery phase. The key challenges for clinical laboratories on the way from discovery to clinical practice of the circulating tumor DNA analysis, including choosing the intended use based on evidence for clinical validity and utility, quality assurance for the testing process, reporting and interpretation for the results will be discussed. \u0000 \u0000 \u0000Key words: \u0000Circulating tumor DNA; Clinical laboratory techniques; Biomarkers","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"35 1","pages":"101-104"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73335101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation on hemolysis, resistance and homology of Staphylococcus cohnii urealyticum","authors":"Lu Wang, Jingrong Cao, Li-yan Ye, Yueyun Shen, Kaisheng Lai, D. Shen","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.02.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.02.016","url":null,"abstract":"Objective \u0000To investigate the characteristics of hemolysis, resistance and homology of Staphylococcus cohnii urealyticum. \u0000 \u0000 \u0000Methods \u0000A retrospective study was carried out on thirteen clinical strains of Staphylococcus cohnii urealyticum. They were re-identified by MALDI-TOF MS. Their colony and hemolytic characteristics on blood agar plates were observed. The co-hemolysis between Staphylococcus cohnii urealyticum and Staphylococcus aureus was demonstrated. The hemolysin genes and drug resistance genes were detected by PCR. Pulsed field gel electrophoresis and mass spectrometry were used to analyze the homology of strains. The susceptibility of strains to antimicrobial agents was detected by agar dilution. \u0000 \u0000 \u0000Results \u0000The confirmed 13 strains of Staphylococcus cohnii urealyticum showed various levels of hemolysis and had enhanced synergistic hemolysis with Staphylococcus aureus. All strains were susceptible to vancomycin and tigecycline. There were 12 strains which carried mecA gene, 7 strains carried cfr gene, 7 strains carried ermC gene. The 13 strains were divided into 3 groups by MALDI-TOF MS, and 6 types by pulsed field gel electrophoresis. \u0000 \u0000 \u0000Conclusions \u0000Clinical strains of Staphylococcus cohnii urealyticum demonstrated various levels of hemolysis which could be enhanced by Staphylococcus aureus. Although they carried different drug resistance genes, they were all susceptible to vancomycin and tigecycline. \u0000 \u0000 \u0000Key words: \u0000Staphylococcus; Drug resistance, bacterial; Sequence homology","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"40 1","pages":"186-190"},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82260701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}